uniQure (NASDAQ:QURE) Given Average Rating of “Moderate Buy” by Brokerages

Shares of uniQure (NASDAQ:QURE) have been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $31.91.

Several analysts have recently issued reports on QURE shares. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of uniQure in a research note on Wednesday. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Friday, March 1st. Mizuho dropped their target price on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday. Royal Bank of Canada restated an “outperform” rating and issued a $28.00 target price on shares of uniQure in a research note on Tuesday, January 16th. Finally, The Goldman Sachs Group downgraded uniQure from a “buy” rating to a “neutral” rating and decreased their price target for the company from $63.00 to $8.00 in a research report on Thursday, February 29th.

uniQure Price Performance

Shares of NASDAQ QURE opened at $4.89 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 8.68 and a current ratio of 8.85. The firm’s 50-day simple moving average is $5.00 and its 200 day simple moving average is $5.88. The stock has a market cap of $233.93 million, a price-to-earnings ratio of -0.75 and a beta of 0.98. uniQure has a fifty-two week low of $4.25 and a fifty-two week high of $22.48.

uniQure (NASDAQ:QURE) last posted its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.01. The company had revenue of $6.69 million for the quarter, compared to analyst estimates of $3.20 million. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. As a group, research analysts anticipate that uniQure will post -4.49 earnings per share for the current fiscal year.

Insider Activity at uniQure

In other uniQure news, COO Pierre Caloz sold 9,455 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the completion of the sale, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at $554,110.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other uniQure news, COO Pierre Caloz sold 9,455 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the transaction, the chief operating officer now owns 85,643 shares in the company, valued at $554,110.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew C. Kapusta sold 27,904 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.35, for a total transaction of $177,190.40. Following the completion of the sale, the chief executive officer now directly owns 440,839 shares in the company, valued at approximately $2,799,327.65. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,265 shares of company stock worth $339,845. Insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

A number of large investors have recently made changes to their positions in QURE. Vestal Point Capital LP bought a new stake in shares of uniQure during the 4th quarter valued at $26,572,000. 683 Capital Management LLC lifted its holdings in shares of uniQure by 21.6% in the third quarter. 683 Capital Management LLC now owns 1,575,000 shares of the biotechnology company’s stock worth $10,568,000 after buying an additional 280,000 shares in the last quarter. Barclays PLC lifted its holdings in shares of uniQure by 527.8% in the third quarter. Barclays PLC now owns 989,562 shares of the biotechnology company’s stock worth $6,641,000 after buying an additional 831,929 shares in the last quarter. Citigroup Inc. boosted its position in shares of uniQure by 667.9% in the third quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock valued at $5,143,000 after acquiring an additional 666,696 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in uniQure by 4.3% during the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock valued at $3,831,000 after acquiring an additional 30,054 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.